Bibliografía

Brantsch  KD, Meisner  C, Schonfisch  B  et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713–20.  [PubMed: 18617440]

Gnann  JW Jr, Whitley  RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340–6.  [PubMed: 12151472]

He  L, Zhang  D, Zhou  M, Zhu  C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2008 Jan23;(1):CD005582.

Lal  H, Cunningham  AL, Godeaux  O  et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.  [PubMed: 25916341]

Kotani  N, Kushikata  T, Hashimoto  H  et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med. 2000;343:1514–9.  [PubMed: 11087880]

Kozel  MM, Mekkes  JR, Bossuyt  PM, Bos  JD. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol. 1998;134:1575–80.  [PubMed: 9875196]

Lens  MB, Dawes  M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150:179–85.  [PubMed: 14996086]

Roujeau  JC, Kelly  JP, Naldi  L  et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.  [PubMed: 7477195]

Simor  AE, Phillips  E, McGeer  A  et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44(2):178–85.  [PubMed: 17173213]

Viard  I, Wehrli  P, Bullani  R  et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490–3.  [PubMed: 9774279]

Xing  XF, Zhou  ZF, Zhang  FJ, Yan  M. The effect of early use of supplemental therapy on preventing postherpetic neuralgia: a systematic review and meta-analysis. Pain Physician. 2017 Sep;20:471–86.